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Abstract
Background
Annually, 10 million adults transition through prisons or jails in the United States (US) and
the prevalence of HIV among entrants is three times higher than that for the country as a
whole. We assessed the potential impact of increasing HIV Testing/Treatment/Retention
(HIV-TTR) in the community and within the criminal justice system (CJS) facilities, coupled
with sexual risk behavior change, focusing on black men-who-have-sex-with-men, 15–54
years, in Atlanta, USA.
Methods
Wemodeled the effect of a HIV-TTR strategy on the estimated cumulative number of new
(acquired) infections and mortality, and on the HIV prevalence at the end of ten years. We
additionally assessed the effect of increasing condom use in all settings.
Results
In the Status Quo scenario, at the end of 10 years, the cumulative number of new infections
in the community, jail and prison was, respectively, 9246, 77 and 154 cases; HIV preva-
lence was 10815, 69 and 152 cases, respectively; and the cumulative number of deaths
was 2585, 18 and 34 cases, respectively. By increasing HIV-TTR coverage, the cumulative
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number of new infections could decrease by 15% in the community, 19% in jail, and 8% in
prison; HIV prevalence could decrease by 8%, 9% and 7%, respectively; mortality could de-
crease by 20%, 39% and 18%, respectively. Based on the model results, we have shown
that limited use and access to condoms have contributed to the HIV incidence and preva-
lence in all settings.
Conclusions
Aggressive implementation of a CJS-focused HIV-TTR strategy has the potential to inter-
rupt HIV transmission and reduce mortality, with benefit to the community at large. To maxi-
mize the impact of these interventions, retention in treatment, including during the period
after jail and prison release, and increased condom use was vital for decreasing the burden
of the HIV epidemic in all settings.
Introduction
In the United States (US), at the end of 2011, it was estimated that 1.1 million people were liv-
ing with HIV/AIDS (PLWHA), and approximately 50,000 individuals became newly infected
yearly [1–4]. The HIV epidemic is very heterogeneous depending on race, age, neighborhood,
gender and other social and economic factors [1, 4]. Among PLWHA, 78% were males, 44%
were African-Americans and 62% were between 35 and 54 years [1–3]. Men-who-have-sex-
with-men (MSM) (62%) contributed the most to PLWHA, followed by high-risk heterosexual
contact (28%) and injection drug use (8%) [1–3]. By year-end 2010, Georgia ranked sixth
among states in terms of HIV/AIDS prevalence rate (429 per 100,000 population) [3].
In parallel, the US is also facing a serious HIV epidemic within the criminal justice system
(CJS) [4, 5]. At year-end 2010, there were 20,093 PLWHA among the 2.3 million adults incar-
cerated (prevalence 0.87%), including 1,578 federal and 18,515 state prisoners. HIV prevalence
among those within the US-CJS is three times greater than those within the community, with
Georgia ranking seventh in the US [5]. Persons of color, especially of black race (mostly Afri-
can-American), are disproportionately affected by HIV and incarceration compared to their
Caucasian counterparts [6, 7]. Though HIV can be transmitted within US-CJS settings through
forced or consensual sex (facilitated by limited condom availability) [8–10], injection drug use
(facilitated by the absence of sterile injecting equipment and near absence of evidence-based
drug treatment)[10], and tattooing [10, 11], most HIV transmission occurs outside the CJS.
Thus, understanding the dynamics of HIV among persons cycling in and out of correctional fa-
cilities is important for developing community-wide HIV prevention strategies.
Over the last decade, expanded HIV testing, antiretroviral (ART) treatment and retention
in long-term treatment (HIV-TTR) has been proposed as a powerful strategy to reduce HIV-
related morbidity and mortality and secondarily decrease HIV transmission [12–15]. Studies
have shown that by decreasing plasma HIV-1 RNA levels to undetectable levels (typically<50
copies/mL) in blood, semen and vaginal secretions on a long-term basis can dramatically re-
duce HIV transmission [12, 16]. Since then, several groups, with exception of MSM communi-
ties in Australia, Amsterdam and in the UK, have shown that for any given increase in ART
coverage a subsequent decrease in HIV transmission can be expected [12, 17].
In the present study, we sought to develop a mathematical transmission model to predict
the community-wide impact of intensifying prevention interventions both within in the
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community and CJS facilities, including expansion of HIV-TTR and sexual risk behavior
changes. The choice of focusing this model on the CJS in Fulton County, Atlanta, Georgia, was
driven by two facts: (1) the management of inmates across CJS facilities in different states in
the US vary dramatically, and by focusing on only one state we minimized biases that could be
introduced in our analyses; and (2) we have access to a selection of rich data sources. Fulton
County is an urban county, which comprises 90% of the city of Atlanta and the most populated
county in Georgia, with very high incarceration rates and HIV incidence and prevalence. In
2012, there were 26,344 male inmates in Fulton County Jail and 51,868 male inmates confined
in all Georgia state prisons. Demographically, Black males are at the highest risk of CJS involve-
ment and HIV infection in Fulton County. In addition, MSM transmission contributes most to
PLWHA in Fulton County for males (91% of new infections); and heterosexual transmission
accounts for 87% of new infections in females) [1–3, 18, 19]. Injection drug use is relatively
rare in Fulton County [19]. To assess the impact of a CJS-based HIV-TTR intervention, this
model was based upon 2012 Fulton County data including persons aged 15–54 years, of black
race, and whose risk for acquiring HIV is MSM through unprotected anal intercourse.
Materials and Methods
Data
Data for population estimates, population growth, HIV/AIDS and non-HIV/AIDS mortality
were obtained from the US Census Bureau, the US Centers for Disease Control (CDC), and the
Georgia Department of Public Health [1–3, 6, 19–30]. HIV testing data in the CJS were ob-
tained from the IIDDEAL study, which was a US CDC demonstration project in Fulton County
Jail [18]. Longitudinal data for the jail setting for ART uptake and retention in treatment were
obtained from the EnhanceLink project, which was a Special Projects of National Significance
funded by the Health Resources and Service Administration HIV/AIDS Program [31–36]. Lon-
gitudinal data for the prison setting for HIV testing, ART uptake and retention in treatment
were obtained from the Georgia Department of Corrections and published literature [37–39].
The size of the incarcerated population and HIV/AIDS and non-HIV/AIDS mortality data in
the CJS were obtained from the Bureau of Justice Statistics and the National Corrections Re-
porting Program [5, 6, 29, 30, 37, 40–43]. We also incorporated published data on HIV testing,
ART uptake and retention in treatment at the community-level based on available data from
the Georgia Department of Public Health and the CDC [19, 20, 22–28]. HIV transmission
probabilities were obtained from published studies among the MSM population [44–46]. Be-
havioral data for the MSM population in the community and while incarcerated were obtained
from published US studies [47–57]. We also obtained longitudinal clinical data for patients
from the British Columbia Centre for Excellence in HIV/AIDS to estimate the plasma viral
load trajectory of MSM patients prescribed ART [58, 59].
Deterministic Compartmental Transmission Model
The model is presented in Fig 1 and a detailed list and explanation of all parameters can be
found in S1 File. Briefly, the model stratified the population according to CJS status into three
groups: individuals residing in the community and those incarcerated in jail and in (state) pris-
on. In the US, jails are confinement facilities administered by local law enforcement agencies
that detain before or after adjudication. Inmates sentenced to jail facilities usually have a sen-
tence of one year or less. Prisons are long-term confinement facilities run by a state or the fed-
eral government that typically hold felons and offenders with sentences of more than one year.
Prisons are long-term confinement facilities run by a state or the federal government that typi-
cally hold felons and offenders with sentences of more than one year. Note that the community
HIV and Incarceration
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Fig 1. Model Description; (A) Movement between Community (C) and Jail (J), (B) Movement between
Jail (J) and Prison (P), and (C) Movement between Prison (P) and Community (C).
doi:10.1371/journal.pone.0123482.g001
HIV and Incarceration
PLOS ONE | DOI:10.1371/journal.pone.0123482 April 23, 2015 4 / 23
compartment included people on probation or on parole, and we did not explicitly model the
effect of recidivism on the risk of acquiring HIV. The possible transitions across settings in the
model included Community!Jail, Jail!Community, Jail!Prison and Prison!Community.
Thus, in order for an individual go from the community to prison, he needs to go first to jail
and then to prison (rarely individuals go directly to prison). Individuals were also stratified ac-
cording to their stage in the HIV continuum of care as: susceptible (i.e. not infected), HIV-
infected but not tested, HIV-infected tested and HIV-infected on ART. In Fulton County in
2012, ART was initiated based on a CD4 cell count threshold of350 cells/mm3 and this is the
criterion used in the Status Quo scenario. We note that the HIV treatment guidelines have
since changed and it is expected that all people be offered ART regardless of CD4. Thus, in all
HIV-TTR expansion scenarios we used this new criterion to determine the benefit for the pop-
ulation from making universal treatment available. For individuals in the HIV-infected not
tested and tested compartments, disease stages were assigned as follows: acutely infected (up to
six months since infection), chronically infected (six months from infection to diagnosis of
AIDS), and late stage (if an individual experienced any AIDS-defining condition) [15, 60].
Among those on ART, we divided the population into different plasma viral load strata
(<3 log10 copies/mL,3 and<4 log10 copies/mL,4 log10 copies/mL) and in a separate com-
partment if the individual experienced any AIDS-defining condition after starting ART [58].
This model was calibrated based on available data for HIV prevalence and new positive tests
in the community, from 2008 to 2012, obtained from the Georgia Department of Public Health
(Fig 2) [19, 22–28]. Note that longitudinal information for these same outcomes for the jail and
prison settings were not available at the Bureau of Justice Statistics and, therefore, we relied on
expert opinion to assess the validity of our model predictions in these settings. In addition, we
compared our model HIV incidence estimates with the results of two studies involving MSM
in Atlanta, Georgia—the HTPN 061 and the InvolveMENt studies (Fig 3) [53–56]. In this cali-
bration, we compared the published data with the model predictions using the two-sample
Kolmogorov-Smirnov test (Fig 3).
Each model run was the result of a different combination of parameter values, and the
model outputs were gathered at every six months for 10 years (2013 to 2022). In this model we
assumed a homogeneous mixing between MSM in each of the settings. A more detailed expla-
nation of the differential equations that govern this model, the parameter values for the Status
Quo scenario and the model’s initial conditions can be found in S1 File. The model was imple-
mented using Berkeley Madonna version 8.3.13.
Main Outcomes
We projected the course of the HIV epidemic in Fulton County by comparing the Status Quo
scenario to different HIV-TTR scenarios in the community, jail, and prison settings. The mea-
sures of intervention impact at the end of 10 years included: (1) the number of averted HIV inci-
dent, prevalent and mortality cases; (2) HIV incidence rates; and (3) the percentage reduction in
HIV incidence, prevalence and mortality. HIV incident cases are equivalent to the number of
newly acquired infections. HIV incidence rates were defined by dividing the estimated HIV inci-
dence by estimates of the size of the susceptible population in a given year. The percent change
was defined by calculating the difference in outcome between the intervention and the Status
Quo scenario in a given year and dividing this by the same outcome in the Status Quo scenario.
Modeling Scenarios
In the community, jail and prison, we estimated the effect of: (1) only increasing testing;
(2) only increasing ART treatment. Here, we considered the approach of initiating therapy just
HIV and Incarceration
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Fig 2. Results for the Model Calibration; (A) New Diagnosed Cases in the Community, and (B)
Prevalent Cases in the Community. Actual data represents the new diagnoses (A) or prevalent (B) cases
reported by the Georgia Department of Public Health [19, 20, 22–28]. Data were compared using the two-
sample Kolmogorov-Smirnov test.
doi:10.1371/journal.pone.0123482.g002
HIV and Incarceration
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after receiving a positive test regardless of CD4 count criteria (i.e. a universal test and treat ap-
proach); and (3) simultaneously increasing testing, ART treatment coverage and retention in
treatment based on a universal test and treat approach. It is important to mention that in both
jail and prison, there is a high rate of treatment interruption (i.e. low retention) for individuals
returning to the community (only 38% are currently retained in care six months post-release
from jail and 30% sixty days after been released from prison) [39, 61]. Therefore, a key inter-
vention in the model was to increase the treatment retention rate upon release from jail
or prison.
Note that all rates in each of the scenarios that we describe next are per 100 persons/6
months. The scenarios in each setting were as follows: (1) Community—we increased HIV test-
ing and ART coverage rates to 60, 80 and 100 and retention in treatment rates to 100; (2) Jail—
currently, Fulton County has an opt-out rapid HIV testing on jail entry and since most jail
episodes are short in length [32, 34, 38], one of the possible interventions was increasing HIV
testing rates to 60, 80 and 100. Since some jail detainees have longer jail episodes, however, we
also increased ART coverage rate to 60, 80 and 100 and retention in treatment rate to 100. In
this model, we did not consider testing once the individual is already in jail since this scenario
is rare based on current jail practice; and (3) Prison—we increased ART coverage rate to 60, 80
and 100 and retention in treatment rate from 95 to 100. Note that currently, in Georgia, HIV
testing on prison entry is mandatory and effectively at 100% [62]. In this model, we did not
consider testing once the individual is already in prison since, in practice, testing does not
occur again until prison discharge or by inmate request.
Fig 3. Comparison of HIV Incidence Curves Based on the Present Model and on Other Growth Models Published on the Literature.Growth 1 was
based on the results from the HTPN 061 study based on all trial participants [53, 55, 56]; Growth 2 was based on the results from the HTPN 061 study based
on trial participants aged 30 years or less [53, 55, 56]; Growth 3 was based on the results from the InvolveMENt study [54]; Growth 4 was based on the
average of the previous growth models; Growth 5 was based on this model’s predictions.
doi:10.1371/journal.pone.0123482.g003
HIV and Incarceration
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Last, in addition to increasing HIV-TTR rates, we assessed the additional benefit of increas-
ing condom use. We based this analysis on the HIV-TTR coverage rate scenarios 60/60/100,
80/80/100 and 100/100/100 per 100 persons/6months. In each of these scenarios we increased
condom use as follows: (1) Community—we increased the condom use from 63% (Status Quo)
of all anal sexual acts to 70%, 75%, 80%, 85% and 90%; (2) Jail and Prison—currently in Geor-
gia, there is no sanctioned condom distribution in both jail and prison. However, to assess
whether any level of condom distribution in this setting would have any additional effect on
HIV incidence and prevalence, we increased the condom use from 0% (Status Quo) of all anal
sexual acts to 30%, 60% and 90%.
Sensitivity Analysis
To evaluate the impact of individual model assumptions, we performed univariate sensitivity
analyses using as basis the parameter values from the Status Quo scenario. The impact of the
sensitivity analyses was assessed by calculating the percent change in HIV incidence and preva-
lence in the community, jail and prison at the end of 10 years. Due to the higher uncertainty in
our behavior parameters, we decided to run these sensitivity analyses focused on increasing the
following parameters, in all settings, by 20%, 40% and 60%: the rates of transmission through
receptive and insertive anal sex, the probability of having unprotected receptive anal sex, and
the product between the average number of anal sexual partners and anal sexual encounters.
We also assessed the impact of condom efficacy on the same model outcomes since the litera-
ture reports on a range for efficacies [57, 63]. In this case, we reduced this parameter by 10%,
15% and 20%. Please refer to S1 File for a detailed description of the value of these parameters
in the Status Quo scenario.
Results
Status Quo Scenario
Table 1 shows the results of HIV new infections, point prevalence and mortality cases generat-
ed by the model under the for the Status Quo scenario at the end of ten years (i.e. year 2022).
The model predicted that between 2013 and 2022, there would be an estimated 9,246 new in-
fections acquired in the community, 77 new infections acquired in jail, and 154 new acquired
infections in prison. The 10-year cumulative number of mortality cases in the community, jail
and prison would be 2,585, 18 and 34 cases, respectively. By 2022, the estimated HIV point
prevalence would be 10,815, 69 and 152 cases in the community, jail and prison, respectively.
Additionally, the model estimated that the HIV incidence rate in year 2022, in the community,
jail and prison would be 3.31, 5.00 and 3.94 per 100 susceptible population/year, respectively.
HIV-TTR Scenarios
Community Setting. Results for the impact for each intervention scenario on model out-
comes in the community are presented in Table 1. The estimated cumulative number of ac-
quired new infections would be between 9,025 (lowest coverage) and 8,975 (highest coverage)
if only Testing coverage was increased (between 221 and 271 averted cases; % decrease from
Status Quo between 2.39% and 2.93%); between 8,864 and 8,735 if only Treatment coverage
was increased (between 382 and 511 averted cases; % decrease from Status Quo between 4.13%
and 5.53%); and between 8,071 and 7,850 if Testing, Treatment and Retention coverage were
simultaneously increased (between 1,175 and 1,396 averted cases; % decrease from Status Quo
between 12.71% and 15.10%). Focusing now on the scenarios in which we simultaneously in-
creased Testing, Treatment and Retention coverage, we observed that the cumulative number
HIV and Incarceration
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Table 1. Population Benefits over 10 Years of Expanded HIV Testing/Treatment/Retention in the Community, Jail and Prison.
Strategy New HIV Acquired Infections All-Cause Mortality HIV Prevalence
N Averted
Cases
% Change from
Status Quo
N Averted
Cases
% Change from
Status Quo
N Averted
Cases
% Change from
Status Quo
Community Setting
Status Quo 9246 − − 2585 − − 10815 − −
Expanded Testing Only
60 per 100 persons/
6months
9025 221 -2.39 2514 71 -2.75 10597 218 -2.01
80 per 100 persons/
6months
8993 253 -2.74 2503 82 -3.17 10568 247 -2.29
100 per 100 persons/
6months
8975 271 -2.93 2495 90 -3.48 10551 264 -2.44
Expanded Treatment
Only
60 per 100 persons/
6months
8864 382 -4.13 2278 307 -11.88 10744 71 -0.65
80 per 100 persons/
6months
8790 456 -4.93 2241 344 -13.31 10710 105 -0.97
100 per 100 persons/
6months
8735 511 -5.53 2218 367 -14.20 10680 135 -1.25
Expanded Testing,
Treatment, Retention
60/60/100 per 100
persons/6months
8071 1175 -12.71 2140 445 -17.21 10062 753 -6.96
80/80/100 per 100
persons/6months
7939 1307 -14.14 2102 483 -18.68 9967 848 -7.84
100/100/100 per 100
persons/6months
7850 1396 -15.10 2077 508 -19.65 9901 914 -8.45
Jail Setting
Status Quo 77 − − 18 − − 69 − −
Expanded Testing Only
60 per 100 persons/
6months
74 3 -3.90 17 1 -5.56 67 2 -2.89
80 per 100 persons/
6months
74 3 -3.90 17 1 -5.56 66 2 -3.25
100 per 100 persons/
6months
73 4 -5.19 17 1 -5.56 66 2 -3.48
Expanded Treatment
Only
60 per 100 persons/
6months
75 2 -2.60 14 4 -22.22 68 0 -0.42
80 per 100 persons/
6months
75 2 -2.60 14 4 -22.22 68 0 -0.71
100 per 100 persons/
6months
74 3 -3.90 14 4 -22.22 68 1 -0.97
Expanded Testing,
Treatment, Retention
60/60/100 per 100
persons/6months
64 13 -16.88 12 6 -33.33 64 5 -7.38
80/80/100 per 100
persons/6months
63 14 -18.18 12 6 -33.33 63 6 -8.29
100/100/100 per 100
persons/6months
62 15 -19.48 11 7 -38.89 62 6 -8.94
(Continued)
HIV and Incarceration
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of mortality cases would be between 2,140 and 2,077 cases (between 445 and 508 averted cases;
% decrease from Status Quo between 17.21% and 19.65%). The point prevalence after 10 years
was estimated to be between 10,062 and 9,901, which is equivalent to a percentage reduction
from the Status Quo scenario between 6.96% and 8.45%. Additionally, the model estimated
that the HIV incidence rate in year 2022 would be between 2.90 and 2.82 per 100 susceptible
population/year.
Jail Setting. Results for the impact for each intervention scenario on the model outcomes
in jail are presented in Table 1. The estimated cumulative number of new infections would be
between 73 (lowest coverage) and 74 (highest coverage) if only Testing coverage was increased
(% decrease from Status Quo between 3.90% and 5.19%); between 75 and 74 if only Treatment
coverage was increased (% decrease from Status Quo between 2.60% and 3.90%); and between
64 and 62 if Testing, Treatment and Retention coverage were simultaneously increased (% de-
crease from Status Quo between 16.88% and 19.48%). Focusing now on the scenarios in which
we simultaneously increased Testing, Treatment and Retention coverage, we observed that the
cumulative number of mortality cases would be between 12 and 11 cases (% decrease from Sta-
tus Quo between 33.33% and 38.89%). The point prevalence after 10 years was estimated to be
between 64 and 62, which is equivalent a reduction from the Status Quo scenario between
7.38% and 8.94%. The model also estimated that the HIV incidence rate in year 2022 would be
between 3.34 and 3.24 per 100 susceptible population/year.
Prison Setting. Results for the impact for each intervention scenario on the model out-
comes in prison are presented in Table 1. Remember that Georgia has 100% testing upon entry
into prison and, therefore we only show the results for treatment and retention interventions.
The estimated cumulative number of new infections was between 152 (lowest coverage) and
150 (highest coverage) if only Treatment coverage was increased (% decrease from Status Quo
between 1.30% and 2.60%), and between 143 and 141 if Testing, Treatment and Retention
Table 1. (Continued)
Strategy New HIV Acquired Infections All-Cause Mortality HIV Prevalence
N Averted
Cases
% Change from
Status Quo
N Averted
Cases
% Change from
Status Quo
N Averted
Cases
% Change from
Status Quo
Prison Setting
Status Quo 154 − − 34 − − 152 − −
Expanded Treatment
Only
60 per 100 persons/
6months
152 2 -1.30 31 3 -8.82 152 0 -0.16
80 per 100 persons/
6months
151 3 -1.95 31 3 -8.82 151 1 -0.46
100 per 100 persons/
6months
150 4 -2.60 30 4 -11.76 151 1 -0.73
Expanded Testing,
Treatment, Retention
100/60/100 per 100
persons/6months
143 11 -7.14 29 5 -14.71 143 9 -5.97
100/80/100 per 100
persons/6months
142 12 -7.79 29 5 -14.71 142 10 -6.67
100/100/100 per 100
persons/6months
141 13 -8.44 28 6 -17.65 141 11 -7.16
A detailed explanation for each of the parameter values for the Status Quo scenario can be found in S1 File.
doi:10.1371/journal.pone.0123482.t001
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coverage were simultaneously increased (% decrease from Status Quo between 7.14% and
8.44%). Focusing now on the scenarios in which we simultaneously increased Treatment and
Retention coverage, we observed that the cumulative number of mortality cases would be be-
tween 29 and 28 cases (% decrease from Status Quo between 14.71% and 17.65%). The point
prevalence after 10 years was estimated to be between 143 and 141, which is equivalent a reduc-
tion from the Status Quo scenario between 5.97% and 7.16%. The model also estimated that
the HIV incidence rate in year 2022 would be between 3.67 and 3.62 per 100 susceptible popu-
lation/year.
Testing/Treatment/Retention plus Condom Use in the Community
Community Setting. Focusing on the intervention scenarios in which we simultaneously
increased Testing, Treatment and Retention coverage, we assessed the additional impact on the
estimated HIV cumulative incidence (over 10 years) and the point prevalence (by 2022) if we
increased condom use in the community from 63% (condom use in the Status Quo scenario)
to 70%, 75%, 80%, 85% and 90% (Table 2). We assessed this impact using the HIV-TTR cover-
age rate scenarios 60/60/100, 80/80/100 and 100/100/100 per 100 persons/6months. We esti-
mated that the estimated number of new acquired infections for the 60/60/100 scenario for the
lowest and highest condom use increase was, respectively, 6,303 cases (1768 averted cases;
% decrease from condom Status Quo, 21.91%) and 2,170 cases (5901 averted cases; % decrease
from condom Status Quo, 73.12%). In addition, we estimated that the estimated prevalence for
the 60/60/100 scenario for the lowest and highest condom use increase was, respectively, 8,594
cases (1,468 averted cases; % decrease from condom Status Quo 14.59%) and 5,176 cases (4,886
Table 2. Population Benefits over 10 Years of Expanded HIV Testing/Treatment/Retention and CondomUse in the Community.
New HIV Acquired Infections
Expanded Testing, Treatment, Retention
plus Condom Use
N Averted Cases % Change
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
C (63%), J(0%), P(0%) 8071 7939 7850 − − − − − −
C (70%), J(0%), P(0%) 6303 6214 6155 1768 1725 1695 -21.91 -21.72 -21.59
C (75%), J(0%), P(0%) 5133 5070 5028 2938 2869 2822 -36.40 -36.13 -35.94
C (80%), J(0%), P(0%) 4052 4010 3982 4019 3929 3868 -49.80 -49.49 -49.27
C (85%), J(0%), P(0%) 3063 3038 3021 5008 4901 4829 -62.05 -61.74 -61.52
C (90%), J(0%), P(0%) 2170 2156 2147 5901 5783 5703 -73.12 -72.84 -72.65
HIV Prevalence
Expanded Testing, Treatment, Retention plus
Condom Use
N Averted Cases % Change
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
C (63%), J(0%), P(0%) 10062 9967 9901 − − − − − −
C (70%), J(0%), P(0%) 8594 8534 8493 1468 1433 1408 -14.59 -14.37 -14.22
C (75%), J(0%), P(0%) 7624 7585 7559 2438 2382 2343 -24.23 -23.90 -23.66
C (80%), J(0%), P(0%) 6728 6707 6692 3333 3260 3209 -33.13 -32.71 -32.41
C (85%), J(0%), P(0%) 5912 5903 5898 4150 4063 4003 -41.24 -40.77 -40.43
C (90%), J(0%), P(0%) 5176 5176 5177 4886 4790 4724 -48.56 -48.06 -47.71
60/60/100, 80/80/100 and 100/100/100 represent rates (per 100 persons/6months) in the intervention scenarios for Testing/Treatment/Retention. Settings:
C—Community, J—Jail and P—Prison. The interventions increased condom use only in the community from 63% to 90%, and maintained condom use in
jail and prison at 0%.
doi:10.1371/journal.pone.0123482.t002
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averted cases; % decrease from condom Status Quo, 48.56%). The model also estimated that
the HIV incidence rate, for the lowest and highest condom use, in year 2022 would be between
2.08 and 0.55 per 100 susceptible population/year. Similar results were obtained for the 80/80/
100 and 100/100/100 scenarios.
Jail and Prison Settings. The secondary benefit of increasing condom use in the commu-
nity was the observed reduction in the estimated new HIV acquired infections and prevalence
in both jail and prison. To demonstrate this benefit, we chose the Testing/Treatment/Retention
coverage rate scenario 60/60/100 per 100 persons/6months.
In jail, the estimated number of new acquired infections for the lowest and highest condom
use increase in the community was, respectively, 60 cases (4 averted cases; % decrease from
condom Status Quo, 5.48%) and 49 cases (15 averted cases; % decrease from condom Status
Quo, 23.11%). The estimated the HIV prevalence for the lowest and highest condom use in-
crease in the community was, respectively, 55 cases (9 averted cases; % decrease from condom
Status Quo, 14.02%) and 34 cases (30 averted cases; % decrease from condom Status Quo,
46.87%). The model also estimated that the HIV incidence rate, for the lowest and highest con-
dom use, in year 2022 would be between 2.89 and 1.79 per 100 susceptible population/year.
In prison, the estimated number of new acquired infections for the lowest and highest con-
dom use increase in the community was, respectively, 139 cases (4 averted cases; % decrease
from condom Status Quo 2.79%) and 127 cases (16 averted cases; % decrease from condom
Status Quo, 11.13%). The estimated the HIV prevalence for the lowest and highest condom use
increase in the community was, respectively, 130 cases (13 averted cases; % decrease from con-
dom Status Quo 9.19%) and 97 cases (46 averted cases; % decrease from condom Status Quo,
32.02%). The model also estimated that the HIV incidence rate, for the lowest and highest con-
dom use, in year 2022 would be between 3.33 and 2.49 per 100 susceptible population/year.
Testing/Treatment/Retention plus Condom Use in Jail and Prison
Focusing on the intervention scenarios in which we simultaneously increased Testing, Treat-
ment and Retention coverage, we assessed the additional impact on the estimated HIV cumula-
tive incidence (over 10 years) and the point prevalence (by 2022) if we increased condom use
in the jail and prison from 0% (condom use in the Status Quo scenario) to 30%, 60% and 90%.
We focused on presenting the results for the HIV-TTR coverage rate scenario 60/60/100 for
jail and 100/60/100 per 100 persons/6months for prison. Note that the scenarios with higher
testing and treatment coverage produced similar results.
In jail, the estimated number of new acquired infections for the lowest and highest condom
use increase was, respectively, 46 cases (18 averted cases; % decrease from condom Status Quo,
28.56%) and 9 cases (55 averted cases; % decrease from condom Status Quo, 85.67%) (Table 3).
The estimated the HIV prevalence did not change significantly across the condom use scenari-
os—e.g., for the highest condom use scenario, the prevalence was 63 cases (1 averted case;
% decrease from condom Status Quo, 1.57%). The model also estimated that the HIV incidence
rate, for the lowest and highest condom use, in year 2022 would be between 2.37 and 0.47 per
100 susceptible population/year.
In prison, the estimated number of new acquired infections for the lowest and highest con-
dom use increase was, respectively, 94 cases (49 averted cases; % decrease from condom Status
Quo, 34.52%) and 16 cases (127 averted cases; % decrease from condom Status Quo, 88.90%)
(Table 4). The estimated the HIV prevalence did not change significantly across the condom use
scenarios—e.g., for the highest condom use scenario, the prevalence was 105 cases (38 averted
cases; % decrease from condom Status Quo, 26.86%). The model also estimated that the HIV
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incidence rate, for the lowest and highest condom use, in year 2022 would be between 2.28 and
0.36 per 100 susceptible population/year.
Sensitivity Analysis
Figs 4 and 5 show the results of the univariate sensitivity analyses on the predicted number of
new HIV acquired infections and HIV prevalence for each of the settings.
Table 3. Population Benefits over 10 Years of Expanded HIV Testing/Treatment/Retention and CondomUse in Jail.
New HIV Acquired Infections
Expanded Testing, Treatment, Retention plus
Condom Use
N Averted Cases % Change
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
C (63%), J(0%), P(0%) 64 63 62 − − − − − −
C (63%), J(30%), P(0%) 46 45 44 18 18 18 -28.56 -28.87 -28.70
C (63%), J(60%), P(0%) 27 27 26 37 36 36 -57.27 -57.45 -57.35
C (63%), J(90%), P(0%) 9 9 9 55 54 53 -85.67 -85.73 -85.69
HIV Prevalence
Expanded Testing, Treatment, Retention plus
Condom Use
N Averted Cases % Change
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
60/60/
100
80/80/
100
100/100/
100
C (63%), J(0%), P(0%) 64 63 62 − − − − − −
C (63%), J(30%), P(0%) 63 63 62 0 0 0 -0.53 -0.52 -0.52
C (63%), J(60%), P(0%) 63 62 62 1 1 1 -1.05 -1.04 -1.04
C (63%), J(90%), P(0%) 63 62 62 1 1 1 -1.57 -1.55 -1.55
60/60/100, 80/80/100 and 100/100/100 represent rates (per 100 persons/6months) in the intervention scenarios for Testing/Treatment/Retention. Settings:
C—Community, J—Jail and P—Prison. The interventions increased condom use only in jail from 0% to 90%, and maintained condom use in the
community at 63% and in prison at 0%.
doi:10.1371/journal.pone.0123482.t003
Table 4. Population Benefits over 10 Years of Expanded HIV Testing/Treatment/Retention and CondomUse in Prison.
New HIV Acquired Infections
Expanded Testing, Treatment, Retention
plus Condom Use
N Averted Cases % Change
100/60/
100
100/80/
100
100/100/
100
100/60/
100
100/80/
100
100/100/
100
100/60/
100
100/80/
100
100/100/
100
C (63%), J(0%), P(0%) 143 142 141 − − − − − −
C (63%), J(0%), P(30%) 94 93 90 49 49 51 -34.52 -34.56 -35.96
C (63%), J(0%), P(60%) 51 51 50 92 91 91 -63.99 -64.02 -64.88
C (63%), J(0%), P(90%) 16 16 15 127 126 126 -88.90 -88.91 -89.20
HIV Prevalence
Expanded Testing, Treatment, Retention plus
Condom Use
N Averted Cases % Change
100/60/
100
100/80/
100
100/100/
100
100/60/
100
100/80/
100
100/100/
100
100/60/
100
100/80/
100
100/100/
100
C (63%), J(0%), P(0%) 143 142 141 − − − − − −
C (63%), J(0%), P(30%) 128 127 126 15 15 15 -10.44 -10.45 -10.46
C (63%), J(0%), P(60%) 115 114 114 28 28 27 -19.38 -19.38 -19.40
C (63%), J(0%), P(90%) 105 104 103 38 38 38 -26.86 -26.86 -26.87
60/60/100, 80/80/100 and 100/100/100 represent rates (per 100 persons/6months) in the intervention scenarios for Testing/Treatment/Retention. Settings:
C—Community, J—Jail and P—Prison. The interventions increased condom use only in prison from 0% to 90%, and maintained condom use in the
community at 63% and in jail at 0%.
doi:10.1371/journal.pone.0123482.t004
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Fig 4. Results from the Univariate Sensitivity Analyses Based on the Percent Change in new HIV acquired infections (i.e. HIV Incidence) and
Prevalence from the Status Quo Scenario; (A) Community, (B) Jail, and (C) Prison. This analysis assumed an increase of 20%, 40% and 60% in the rate
of transmission through anal receptive (ξreceptive) and insertive (ξinsertive)sex, in the probability of having unprotected receptive anal sex (pr), and in the product
between the average number of anal sexual partners and anal sexual encounters (np*ne).
doi:10.1371/journal.pone.0123482.g004
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New HIV acquired infections. In the community, these estimates were highly sensitive to
the rate of transmission through receptive and insertive anal sex, to the product between the
average number of anal sexual partners and anal sexual encounters, and to the probability of
having unprotected receptive anal sex, and they were less sensitive to the value used for con-
dom efficacy. In both jail and prison, these estimates were most sensitive to the rate of trans-
mission through receptive and insertive anal sex, and less sensitive to the probability of having
unprotected receptive anal sex and to the product between the average number of anal sexual
partners and anal sexual encounters.
HIV prevalence. In the community, these estimates were highly sensitive to the rate of
transmission through anal receptive and insertive sex, to the product between the average
number of anal sexual partners and anal sexual encounters, and to the probability of having un-
protected receptive anal sex, and they were less sensitive to the value used for condom efficacy.
In jail, these estimates were highly sensitive to the rate of transmission through anal receptive
and insertive sex and to the product between the average number of anal sexual partners and
anal sexual encounters, and they were less sensitive to the probability of having unprotected re-
ceptive anal sex. In prison, these estimates were highly sensitive to the rate of transmission
through anal receptive and insertive sex, and they were less sensitive to the product between
the average number of anal sexual partners and anal sexual encounters, and to the probability
of having unprotected receptive anal sex.
Discussion
Wemodeled the impact of increasing HIV testing, treatment, and retention in treatment on the
HIV epidemic in Fulton County in the black MSM community (at large) and among those who
became incarcerated. The model showed that for different scenarios of HIV-TTR we could ex-
pect substantial reductions in HIV incidence, prevalence and mortality. The model also showed
that in order to maximize the impact of increased testing and treatment coverage in decreasing
all model outcomes, retention in treatment in all settings, including the period after jail and
Fig 5. Results from the Univariate Sensitivity Analyses Based on the Percent Change in new HIV acquired infections (i.e. HIV Incidence) and
Prevalence from the Status Quo Scenario. This analysis assumed a decrease of 10%, 15% and 20% in condom efficacy (parameter δ).
doi:10.1371/journal.pone.0123482.g005
HIV and Incarceration
PLOS ONE | DOI:10.1371/journal.pone.0123482 April 23, 2015 15 / 23
prison release, was vital for the success of these interventions. Different studies have pointed
out that retention in treatment is essential for the success of any expansion of HIV testing and
treatment aimed at preventing future HIV infections [64]. It is important to mention that our
model retention parameters encompassed both pre-release and post-release retention in treat-
ment, given that a major issue in this population is the discontinuation of healthcare benefits
and treatment upon release from correctional facilities [61, 65–69]. Several studies have demon-
strated that the period after release from incarceration can be quite difficult and disruptive
since individuals may face several issues including social-economic and health challenges, and
in addition, this period may be accompanied by increased sexual behavior [39, 70, 71].
In addition, the model demonstrated that there is a strong additive benefit of expanded con-
dom use in the community setting. In this case, we showed that HIV-TTR interventions alone
would not decrease incidence rate below 1 per 100 susceptible population/year at the end of ten
years. To decrease the HIV incidence rate below 1 in the community, we needed to significantly
increase condom use in the community. These findings independently confirm the results of a
mathematical model built to address the MSM epidemic in the United Kingdom [72]. In this
case, the authors stressed that condom use should be highly promoted in the population to
maximize the benefits of expanded access to HIV testing and treatment. Thus, we stress the im-
portance of implementing interventions involving education and condom distribution to re-
duce risk behavior in the community and, very importantly, during the critical post-release
period. Nationwide, most jails and prisons, including those in Georgia, do not distribute con-
doms to their inmates, and recently California changed its regulations [73]. Based on the
model results, we have shown that lack of access to condoms contributes to the HIV incidence
in these settings to remain above 1 per 100 susceptible population/year.
An important consideration in building this model was determining which interventions
were feasible in jail and in prison, since they may be highly dependent on the length of stay of
different inmates. Among the interventions considered in this study, HIV testing, ART provi-
sion and retention in care are highly feasible in prison, since prison episodes are long in nature
[74]. In jail, the length of stay is usually short and there is rapid turnover of inmates [32–34]. In
this setting, the only in-facility intervention considered was HIV testing. Since some jail detain-
ees have longer episodes, however, in addition to increasing testing, we should also consider in-
creasing ART treatment uptake and encouraging retention into HIV treatment. A recent study
conducted in Rhode Island Department of Corrections jail confirmed the feasibility of provid-
ing ART treatment when jail incarceration events were greater than 60 days [75]. The extent to
which the provision of and retention in treatment may be as successful as when implemented in
prison (more stable environment) is unknown though recent data from Connecticut suggests
that prescribing ART soon after jail admission results in high levels of viral suppression [74]. It
is important to mention that provision of routine HIV screening upon jail or prison entry and
ART coverage varies significantly geographically [35, 76–81]; however these settings present the
best opportunity to identify undiagnosed infections and to link individuals into care, since for
this population, this might be the best opportunity to access proper healthcare services.
Going beyond the mathematical modeling domain, the key question is how to translate the
potential that HIV-TTR interventions have in halting the HIV epidemic when dealing with
hard-to-reach populations, and how to use these interventions to help reduce racial and social
inequalities surrounding the HIV epidemic among correctional populations [82, 83]. One issue
not addressed in our model was the effect of recidivism on the risk of HIV infection, which is
quite prevalent in Fulton County, Georgia and across the US [61, 82]. Unfortunately, many of
these individuals remain at a great risk for not accessing any healthcare upon release and the
benefits attained by being on ART can be lost in the long-term, thus promoting HIV transmis-
sion [65, 66, 68–70]. Therefore, for these interventions to be successful, the lives of those
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released from the CJS need to be stabilized through access to housing, employment opportuni-
ties, substance abuse treatment, and healthcare entitlements [6, 39, 55, 84]; all of these benefits
need to remain in place despite incarceration events.
Our results were based on a mathematical model with important implications and limita-
tions. First, this model is quite intricate because it requires a large number of parameter esti-
mates, and while most parameters were based on empirical data, our behavior parameters were
susceptible to a high degree of uncertainty. In particular, caution should be applied when ex-
trapolating these results to other jurisdictions. Another important assumption in this model,
mostly for simplification purposes, referred to the transitions between community and CJS. To
this end, we assumed that in order for individuals to go to prison they needed to go through
jail, and we did not explicitly model transitions among other settings such as probation, parole
or alternative programs. We do not believe that modifying the model structure, however, to ad-
dress this limitation would have a great impact on our projections since these last individuals
were modeled as being in the community. Third, we did not model the effect of different co-
morbid conditions on the risk of HIV acquisition/transmission in this population. It is well
known that drug and alcohol addiction, mental illnesses and sexually transmitted infections
significantly modulate the risks of incarceration and HIV acquisition/transmission [61, 76, 77].
Although these issues are clearly important determinants of the impact of the HIV epidemic in
this population, modeling their effect would greatly increase the model complexity and is be-
yond the scope of this study. Fourth, in this model we did not consider behavior interventions
initiated by the health services staff [85, 86]. To assess the impact of such behavior interven-
tions we can use the results of our analysis, since we showed that the provision and consistent
use of condoms are viable interventions to halt the spread of HIV. Fifth, we tried to calibrate
our model beyond using prevalence and new cases data in the community. Unfortunately, lon-
gitudinal data for several other model outcomes were not available for all settings. Sixth, some
studies have reported on as much as 50% reduction in risk behavior upon HIV diagnosis or
entry into ART treatment [87, 88]. In this study, we did not consider this additional parameter
because the population in these studies was different than ours, although there is some evi-
dence that this reduction in risk could be mirrored in our population [11]. Seventh, the longitu-
dinal viral load distribution was based on the MSM population on ART therapy from a
different setting from Atlanta. We chose to take this approach since representative longitudinal
data focused on our study population were not available. Eighth, in this model we assumed a
homogeneous mixing between MSM in each of the settings. In reality, movement is not ran-
dom within the confines of a jail or prison, especially for those in solitary confinement. Fur-
thermore, there may not be randommixing in sexual positioning; MSM could have
preferences for exclusively insertive or receptive, or versatile behavior. Although mixing is an
important component in this type of modeling since it can influence the overall HIV incidence
and prevalence, obtaining information on this issue is extremely difficult for our study popula-
tion and caution should be exercised when making any assumptions in this regard. This limita-
tion highlights the importance of collecting information on MSM sexual mixing preferences in
each of the settings so that future models in this population can be more comprehensive.
Ninth, the model did not include testing during incarceration, beyond testing done at admis-
sion, since this occurs rarely in Fulton County jail or in Georgia’s prisons. However, we built a
model flexible enough to assess the effect of testing among inmates if this practice is modified
in the future. Finally, it is important to highlight that while we obtained a small yet important,
effect on HIV incidence, prevalence and mortality by implementing a HIV-TTR strategy in jail
and in prison, we stress that implementing such strategy without focusing on any particular
risk group in these settings (e.g., individuals with known high risk behaviour) would have the
lowest effect on these outcomes. Therefore, we believe that targeting specific risk groups when
HIV and Incarceration
PLOS ONE | DOI:10.1371/journal.pone.0123482 April 23, 2015 17 / 23
implementing a HIV-TTR strategy in jail and in prison would potentially yield the highest ef-
fect on these outcomes.
In conclusion, the HIV and incarceration epidemics are highly interconnected and correc-
tional facilities across the US play a major role in providing HIV testing and treatment. The jail
and prison settings offer a great opportunity to implementing HIV-TTR strategies to reduce the
spread of HIV within the incarcerated population and the community at large. However, the
success of this strategy is contingent upon ensuring retention in HIV care after release from jail
or prison. This analysis serves as a call to action for public health officials, criminal justice health
administrators, and HIV care providers to examine the implementation of Test/Treat/Retain in-
terventions, along with the promotion of condom use among negative and HIV-infected MSM
individuals in the community setting. Additionally, we hope that the additional population-level
benefit illustrated in this study of condom use in jails and prisons can facilitate future discus-
sions regarding the possibility of introducing condom distribution as another possible harm-re-
duction strategy in the CJS setting.
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